Literature DB >> 10673190

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

S Miyamoto1, N Nagaya, T Satoh, S Kyotani, F Sakamaki, M Fujita, N Nakanishi, K Miyatake.   

Abstract

The six-minute walk test is a submaximal exercise test that can be performed even by a patient with heart failure not tolerating maximal exercise testing. To elucidate the clinical significance and prognostic value of the six-minute walk test in patients with primary pulmonary hypertension (PPH), we sought (1) to assess the relation between distance walked during the six-minute walk test and exercise capacity determined by maximal cardiopulmonary exercise testing, and (2) to investigate the prognostic value of the six-minute walk test in comparison with other noninvasive parameters. The six-minute walk test was performed in 43 patients with PPH, together with echocardiography, right heart catheterization, and measurement of plasma epinephrine and norepinephrine. Symptom-limited cardiopulmonary exercise testing was performed in a subsample of patients (n = 27). Distance walked in 6 min was significantly shorter in patients with PPH than in age- and sex-matched healthy subjects (297 +/- 188 versus 655 +/- 91 m, p < 0. 001). The distance significantly decreased in proportion to the severity of New York Heart Association functional class. The distance walked correlated modestly with baseline cardiac output (r = 0.48, p < 0.05) and total pulmonary resistance (r = -0.49, p < 0. 05), but not significantly with mean pulmonary arterial pressure. In contrast, the distance walked correlated strongly with peak V O(2) (r = 0.70, p < 0.001), oxygen pulse (r = 0.57, p < 0.01), and V E-VCO(2) slope (r = -0.66, p < 0.001) determined by cardiopulmonary exercise testing. During a mean follow-up period of 21 +/- 16 mo, 12 patients died of cardiopulmonary causes. Among noninvasive parameters including clinical, echocardiographic, and neurohumoral parameters, only the distance walked in 6 min was independently related to mortality in PPH by multivariate analysis. Patients walking < 332 m had a significantly lower survival rate than those walking farther, assessed by Kaplan-Meier survival curves (log-rank test, p < 0.01). These results suggest that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.

Entities:  

Mesh:

Year:  2000        PMID: 10673190     DOI: 10.1164/ajrccm.161.2.9906015

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  215 in total

Review 1.  Pulmonary arterial hypertension: new ideas and perspectives.

Authors:  N Galiè; A Torbicki
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

2.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 3.  N-TproBNP as biomarker in systemic sclerosis.

Authors:  Tommaso Schioppo; Carolina Artusi; Teresa Ciavarella; Francesca Ingegnoli; Antonella Murgo; Silvana Zeni; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

4.  Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Bastiaan E Scholzel; Martijn C Post; H W Thijs Plokker; Repke J Snijder
Journal:  Lung       Date:  2011-12-08       Impact factor: 2.584

Review 5.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

6.  Atrial septostomy for pulmonary arterial hypertension.

Authors:  R J Allcock; J J O'Sullivan; P A Corris
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

Review 7.  A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

Authors:  E Hachulla; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

Review 8.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

9.  Heart rate response to a timed walk and cardiovascular outcomes in older adults: the cardiovascular health study.

Authors:  Saket Girotra; Dalane W Kitzman; Willem J Kop; Phyllis K Stein; John S Gottdiener; Kenneth J Mukamal
Journal:  Cardiology       Date:  2012-06-20       Impact factor: 1.869

10.  Heat stress is associated with reduced health status in pulmonary arterial hypertension: a prospective study cohort.

Authors:  Melissa Jehn; Andreas Gebhardt; Uta Liebers; Bahar Kiran; Dieter Scherer; Wilfried Endlicher; Christian Witt
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.